Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data

First scientific presentation of detailed MAESTRO-NASH results confirms achievement of primary endpoints across multiple patient subgroupsNoninvasive...

Related Keywords

United States ,Texas ,San Antonio ,Vienna ,Wien ,Austria ,Stephen Harrison ,Becky Taub ,Alex Howarth ,Madrigal Pharmaceuticals Inc ,Registration Program For The Treatment ,Exchange Commission ,Research Development Of Madrigal ,Oxford University ,Nasdaq ,Summit Clinical Research ,Madrigal Pharmaceuticals ,Pinnacle Clinical Research ,European Association ,Liver Congress ,Visiting Professor ,Principal Investigator ,Chief Medical Officer ,Being Presented ,Investor Event ,Resmetirom Phase ,Private Securities Litigation Reform Act ,Accelerated Approval ,New Drugs ,Life Threatening Illnesses ,Annual Report ,Nasdaq Mdgl ,Nc ,Biotechnology ,Cash ,Vafld ,